Artbits |
23 April
Labiana closed the 2024 fiscal year with revenues of €66.26 million, representing a 13.3% increase compared to the previous year.
Labiana |
25 March
Labiana, the pharmaceutical laboratory specialized in animal and human health listed on BME Growth, has added Lexylan, a new antibiotic classified as Category C in its prescription guidelines, to its product portfolio.
Labiana |
21 March
Labiana, the pharmaceutical laboratory specialized in both animal and human health listed on BME Growth, is expanding its business in the human health sector with the launch of a product line dedicated entirely to the well-being and care of women.
Labiana |
26 September
Labiana, el laboratorio farmacéutico especializado en salud animal y humana cotizado en el BME Growth, se posiciona como laboratorio experto en el análisis de flor del cannabis con fines terapéuticos, lo que permitirá a las compañías que se encargan de su distribución a nivel mundial, su liberación al mercado.
Labiana |
26 June
Labiana divests its Serbian subsidiary through a capital increase agreement
Labiana |
31 May
Labiana, el primer laboratorio veterinario español cotizado en Bolsa, ha hecho público su informe de resultados mostrando un incremento en su facturación en 2023
